175202-48-9

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 4-CYANO-5-(METHYLTHIO)THIOPHENE-2-CARBOXYLATE is used as a key intermediate in the synthesis of pharmaceutical drugs for its ability to contribute to the development of new medicinal compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, METHYL 4-CYANO-5-(METHYLTHIO)THIOPHENE-2-CARBOXYLATE is used as a precursor in the production of pesticides and herbicides, leveraging its chemical properties to enhance the effectiveness of these agricultural chemicals.
Used in Organic Synthesis:
METHYL 4-CYANO-5-(METHYLTHIO)THIOPHENE-2-CARBOXYLATE is utilized as a building block in organic synthesis, particularly for the creation of heterocyclic compounds, which are essential in various chemical and material applications.
Used in Materials Science:
This chemical compound is also employed in materials science, where it contributes to the development of new materials with specific properties, such as improved stability or reactivity, for use in various industrial applications.

InChI:InChI=1/C8H7NO2S2/c1-11-7(10)6-3-5(4-9)8(12-2)13-6/h3H,1-2H3

Upstream product

• 129332-45-2 methyl 3-amino-4-cyano-5-(methylsulfanyl)-2-thiophenecarboxylate 
• 5147-80-8 [Bis(methylthio)methylene]malononitrile 

Downstream Products

• 1247825-27-9 4-cyano-5-[(3,5-dichloropyridin-4-yl)thio]-N-{4-[3-(dimethylamino)propoxy]phenyl} thiophene-2-carboxamide 

Relevant academic research and scientific papers

Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47

Inhibitors of the cancer-related cysteine isopeptidase human ubiquitin-specific proteases 7 (USP7) and 47 (USP47) are considered to have potential as cancer therapeutics, owing to their ability to stabilize the tumor suppressor p53 and to decrease DNA polymerase β(Polβ), both of which are potential anticancer effects. A new class of dual small molecule inhibitors of these enzymes has been discovered. Compound 1, a selective inhibitor of USP7 and USP47 with moderate potency, demonstrates inhibition of USP7 in cells and induces elevated p53 and apoptosis in cancer cell lines. Compound 1 has been shown to demonstrate modest activity in human xenograft multiple myeloma and B-cell leukemia in vivo models. This activity may be the result of dual inhibition of USP7 and USP47. To address issues regarding potency and developability, analogues of compound 1 have been synthesized and tested, leading to improvements in potency, solubility, and metabolic reactivity profile. Further optimization is expected to yield preclinical candidates and, ultimately, clinical candidates for the treatment of multiple myeloma, prostate cancer, and other cancers.

Synthesis of thiophene-2-carboxamidines containing 2-aminothiazoles and their biological evaluation as urokinase inhibitors

The serine protease urokinase (uPa) has been implicated in the progression of both breast and prostate cancer. Utilizing structure based design, the synthesis of a series of substituted 4-[2-amino-1,3-thiazolyl]-thiophene-2-carboxamidines is described. Further optimization of this series by substitution of the terminal amine yielded urokinase inhibitors with excellent activities.